Background {#Sec1}
==========

Despite advances in treatment, the prognosis of head and neck squamous cell carcinoma (HNSCC) patients remains poor. In the setting of definitive treatment, adding chemotherapy concurrently to radiotherapy improves progression-free survival (PFS), overall survival (OS), and organ preservation \[[@CR1]\]. Despite advances, 5-year survival in HPV-negative and HPV-positive patients is 45 and 75%, respectively \[[@CR1], [@CR2]\]. For patients with locally advanced disease and heavy smoking history, the outcomes are far worse, approximating a survival rate of 25% at 5 years \[[@CR3]\]. The presence of metastatic disease in HNSCC invariably portends a poorer prognosis, with treatment often limited to palliative regimens and an average survival of only 4--7 months \[[@CR4]\].

Given the critical need to better understand these aggressive oncologic processes, there has been a concerted effort to identify features that impede, augment, or otherwise influence disease endpoints. Inflammation plays an important role in tumor development, progression, response to therapy and metastasis \[[@CR5], [@CR6]\]. Clinically, increasing evidence suggests that neutrophils, both those circulating in blood and those infiltrating tumors, may drive tumor progression and metastasis \[[@CR7]--[@CR10]\]. A number of studies have linked increased levels of circulating neutrophils with significantly worsened outcomes including OS in non-small cell lung cancer \[[@CR11]\], cervical cancer \[[@CR12]\], prostate cancer \[[@CR13], [@CR14]\], gastric cancers \[[@CR15]--[@CR17]\], bladder cancer \[[@CR18]\] and colorectal cancer \[[@CR19]\]. Several reports have recently detailed the role of both circulating \[[@CR20], [@CR21]\] and tumor infiltrating neutrophils \[[@CR22]\] as predictors of survival in HNSCC as well and their role in promoting of distant metastasis \[[@CR23]\].

Additional prognostic value has been shown with the neutrophil-to-lymphocyte ratio (NLR) with higher values portending poor survival \[[@CR24]--[@CR26]\]. Circulating lymphocyte counts have been independently shown to improve OS in malignancy, with Rachidi et al. specifically highlighting their prognostic value in HNSCC \[[@CR24], [@CR28]\].

Here, we investigate the prognostic value of circulating neutrophil and lymphocyte counts as well as NLR at multiple time points on OS, cancer-specific survival (CSS), local control (LC) and distant control (DC) in patients diagnosed with oropharyngeal and laryngeal cancer.

Methods {#Sec2}
=======

Data source and patient selection {#Sec3}
---------------------------------

We identified 356 patients with squamous cell carcinoma of the oropharynx or larynx diagnosed between 2006 and 2015 with available follow up and treatment outcomes who were treated with curative-intent radiation therapy (RT) within the University of Colorado Hospital system (n = 336) and the University of New Mexico Hospital (n = 20) systems. In order to ensure adequate assessment of response to treatment without potential confounding of post-treatment changes on imaging scans, patients were excluded if they had fewer than 6 months of follow up from completion of treatment \[[@CR29]\]. Patients must have received minimum of two blood draws for complete blood count with differential during the period stretching from 1 month prior to initiation of treatment, including chemotherapy and radiation, through 1 month post-treatment. Additionally, patients were excluded if the radiation treatment course was prolonged by greater than 1 week past the planned completion date. A total of 196 patients met these criteria.

Patient demographics and treatment variables {#Sec4}
--------------------------------------------

All patients received external beam radiation to a minimum dose of 54 Gray (Gy) (range 54--70 Gy, median 69.3 Gy, standard deviation (SD) 3.98 Gy) using 1.8--2.25 Gy/fraction. A total of 5 patients received less than 60 Gy. The median number of radiation treatments was 33 (range 27--35) over an average of 48 days. Potentially relevant patient and treatment characteristics were included. Age at diagnosis was analyzed categorically based on the approximate median age of 60 years. Race was categorized as white or other. Performance status was categorized according to the Karnofsky Performance Score (KPS) as ≤80 or \>80 \[[@CR30]\]. T-classification and N-classification were recorded according to the American Joint Committee on Cancer (AJCC) classification 2002 and 2010 editions based on date of diagnosis. Tobacco use was divided into \<10 or ≥10 pack years \[[@CR31]\]. Patients were considered post-operative if they had received any of the following: subtotal resection, gross total resection, or neck dissection (ipsilateral or bilateral). Chemotherapy was analyzed as a binary variable (yes/no). Additional analyses included steroid use as a binary variable with \>100 mg oral equivalents of dexamethasone versus \<100 mg and chemotherapy regimens stratified into none, cisplatin weekly, cisplatin every 3 weeks (q3), carboplatin plus paclitaxel and cisplatin plus cetuximab.

The cohort was divided into tertiles by neutrophil count (tertile 1: ≤3.2 × 1000 mm^3^ (n = 65), tertile 2: 3.2--4.4 × 1000 mm^3^ (n = 66) and tertile 3: \>4.4 × 1000 mm^3^ (n = 65), and Kaplan--Meier analysis was performed. For multivariate analysis (MVA), the neutrophil and lymphocyte counts were assessed as continuous variables. The primary endpoints were OS, CSS, LC and DC. Survival was determined from the date of diagnosis to the date of death or most recent follow-up. Cancer-specific survival was defined as cancer survival unrelated to other causes of death. Local failure included recurrence or progression in the primary tumor bed and surrounding tissues or regional lymph nodes. Distant failure was defined as a site of disease outside of the tumor bed and regional lymph nodes that was not present during initial therapy.

Definition of white blood cell counts {#Sec5}
-------------------------------------

Three time-periods were defined during the treatment course for collection of absolute neutrophil count (ANC) and absolute lymphocyte count (ALC): (1) 1 month prior to initiation of any treatment (pre-treatment), (2) 1 week to 1 month post-treatment (post-treatment) and (3) containing all time periods from pre-treatment to post-treatment (overall). For the collection of pre-treatment counts, values were taken from the day of treatment initiation whenever possible (190 of 196 patients). For the remaining time points, the lowest value, or nadir, of the ANC and ALC during each respective time period were collected. Analyses were performed at each time period for the ANC, ALC and NLR. The data was then combined over all time-periods and the lowest ANC and ALC observed were selected to represent the overall nadir for analysis. Additionally, the absolute difference in neutrophil count from pre-treatment to post-treatment was collected for analysis.

Statistical analysis {#Sec6}
--------------------

All statistical analyses were performed using SPSS V23.0 (SPSS Inc., Chicago, IL). Pearson Chi square tests were used to assess associations between categorical variables and blood counts. Median follow up was calculated using the reverse KM method \[[@CR31]\]. OS, CSS, LC and DC were first examined using the KM method. Univariate survival analysis (UVA) was performed with the log-rank test and unadjusted Cox proportional hazards models to estimate hazard ratios (HR), with HR \>1 corresponding to worse OS, CSS, LC and DC. Patient and clinical variables were selected a priori. Multivariate Cox regression analysis was performed on all blood counts found to be significant (*p* \< 0.05) on UVA using OS, CSS, LC and DC as outcomes with a significance level of *p* \< 0.05.

Results {#Sec7}
=======

Among our 196 patients, median follow up was 2.7 years (range 0.5--10.8). Median population age was 58 years (range 27--81 years). 171 patients were Stage III or IV. For patients who received chemotherapy (n = 182), regimens included cisplatin (weekly or q3 weeks), carboplatin plus paclitaxel, cetuximab or cisplatin plus cetuximab. In total, 30 patients (15.3%) experienced local failure and 21 patients (10.7%) experienced distant metastasis. Of local failures, 5 patients experienced disease progression in the local tumor bed, while 25 patients experienced a complete response to therapy followed by local recurrence. Of the 21 metastases, 16 were found in the lungs, 4 were found in bone and 1 patient experienced failure in both the lung and bone. The average times to progression, local recurrence, and distant failure were 0.60 years, 1.44 years and 1.53, respectively. There were 7 HPV positive patients with laryngeal primaries. The remaining 92 patients were oropharyngeal primaries. Of the oropharyngeal patients, 28/145 had unknown HPV status. Patient and treatment characteristics are presented in Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristicsAll patients (n = 196)\#%Age at diagnosis, years \<6012061.2 \>607638.8Primary site Oropharynx14574.0 Larynx5126.0Gender Male17187.2 Female2512.8Race White17125 Other87.212.8Tobacco use (pack years) \<1010654.1 ≥109045.9Karnofsky performance score \>8014071.4 ≤805628.6T-stage T110252 T25628.6 T33015.3 T484.1N-stage N0--16131.1 N2a--2b9146.4 N2c--34422.4Post-operative radiation Yes4824.5 No14875.5HPV Negative5126 Positive9950.5 Unknown4623.5Chemotherapy None147.1 Cisplatin, weekly3819.4 Cisplatin, q3 weeks3919.9 Carboplatin + paclitaxel3819.4 Cetuximab5729.1 Cisplatin + cetuximab105.1Overall survival, years Median2.7 Mean3.39 95% CI3.04--3.75

Analysis of the absolute and relative difference between the pre-treatment and post-treatment neutrophil counts for each patient revealed no significant difference in any endpoints (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The majority of patients (68%) experienced a decline in neutrophil count, though the average absolute change in neutrophil count from pre-treatment to post-treatment was \<1 × 1000 mm^3^. Six percent of patients experienced no change in neutrophil count, while 26% of patients experienced an increase in neutrophil count from pre-treatment to post-treatment with an average gain of 1.5 × 1000 mm^3^.

Analysis of patient characteristics {#Sec8}
-----------------------------------

Univariate analysis *p* values of each patient characteristic for all endpoints are presented in Table [2](#Tab2){ref-type="table"}. OS was significantly worse for patients with tobacco use ≥10 pack-years, T-3--4 and HPV-negative status. CSS was worse among those with KPS ≤80, and T-classification 3--4. A decrease in LC was seen in patients with T-classification 3--4 and HPV-negative status. There were no factors that independently correlated to decreased DC. Factors that did not influence any endpoints include age, primary site, gender, race, nodal status, post-operative status and receipt of chemotherapy. Pearson Chi square analysis of chemotherapy regimens with overall neutrophil nadir did not indicate a significant correlation (0.039, *p* = 0.60). Similarly, no correlation was observed between receipt of steroids and overall neutrophil nadir during the treatment period (*r* = 0.18, *p* = 0.14). Univariate analysis of RT dose as a continuous variable did not reveal a significant correlation with OS or CSS (HR, 1.00; 95% CI 1.00--1.01; p = 0.41 and HR, 1.00; 95% CI 0.99--1.00; p = 0.91, respectively).Table 2Univariate analysis of patient characteristics, p valuesOverall survivalCancer-specific survivalLocal controlDistant controlAge at diagnosis, years \<60 vs. ≥60HR, 1.72; 95% CI 0.92--3.20; *p* = 0.09HR, 0.83; 95% CI 0.48--1.44; *p* = 0.51HR, 1.34; 95% CI 0.64--2.79; *p* = 0.44HR, 1.03; 95% CI 0.43--2.48; *p* = 0.95Primary site Oropharynx vs larynxHR, 1.56; 95% CI 0.81--2.99; *p* = 0.18HR, 0.84; 95% CI 0.45--1.55; *p* = 0.57HR, 1.82; 95% CI 0.86--3.85; *p* = 0.12HR, 1.20; 95% CI 0.47--3.10; *p* = 0.71Gender M vs FHR, 0.68; 95% CI 0.24--1.91; *p* = 0.46HR, 0.59; 95% CI 0.24--1.48; *p* = 0.26HR, 0.69; 95% CI 0.21--2.29; *p* = 0.55HR, 0.62; 95% CI 0.15--2.68; *p* = 0.53Race White vs otherHR, 1.24; 95% CI 0.52--2.95; *p* = 0.63HR, 0.98; 95% CI 0.45--2.18; *p* = 0.98HR, 1.24; 95% CI 0.5202.95; *p* = 0.59HR, 0.37; 95% CI 0.05--2.74; *p* = 0.33Tobacco use (pack years) \<10 vs. ≥10*HR*, *2.97*; *95% CI 1.48*--*5.97*; *p* \< *0.01*HR, 1.31; 95% CI 0.78--2.21; *p* = 0.31HR, 1.92; 95% CI 0.89--4.13; *p* = 0.10HR, 1.41; 95% CI 0.59--3.34; *p* = 0.44Karnofsky performance score \>80 vs. ≤80HR, 0.97; 95% CI 0.50--1.89; *p* = 0.94*HR*, *0.48*; *95% CI 0.25*--*0.92*; *p* = *0.03*HR, 1.23; 95% CI 0.58--2.63; *p* = 0.59HR, 1.16; 95% CI 0.47--2.83; *p* = 0.75T-stage T1/2 vs T3/4*HR*, *2.83*; *95% CI 1.47*--*5.44*; *p* \< *0.01HR*, *6.47*; *95% CI 3.34*--*12.52*; *p* \< *0.01HR*, *2.21*; *95% CI 1.42*--*3.44*; *p* \< *0.01*HR, 1.53; 95% CI 0.65--3.64; *p* = 0.33N-stage N0-1 vs N2/3HR, 0.98; 95% CI 0.51--1.89; *p* = 0.96HR, 1.65; 95% CI 0.90--3.02; *p* = 0.10HR, 0.79; 95% CI 0.37--1.67; *p* = 0.53HR, 1.26; 95% CI 0.49--3.26; *p* = 0.63Post-operative radiation Yes vs NoHR, 0.70; 95% CI 0.32--1.52; *p* = 0.37HR, 1.01; 95% CI 0.56--1.82; *p* = 0.97HR, 0.47; 95% CI 0.16--1.36; *p* = 0.17HR, 1.70; 95% CI 0.70--4.12; *p* = 0.24HPV Positive vs negative*HR*, *0.32*; *95% CI 0.15*--*0.67*; *p* \< *0.01*HR, 1.00; 95% CI 0.55--1.84; *p* = 0.98*HR*, *0.25*; *95% CI 0.10*--*0.62*; *p* \< *0.01*HR, 0.49; 95% CI 0.19--1.27; *p* = 0.14Chemotherapy (v none) YesHR, 1.43; 95% CI 0.34--5.94; *p* = 0.62HR, 1.45; 95% CI 0.45HR, 1.19; 95% CI 0.28--5.03; *p* = 0.81HR, 1.90; 95% CI 0.25--14.19; *p* = 0.50 Cisplatin, weeklyHR, 1.14; 95% CI 0.23--5.64; *p* = 0.88HR, 1.21; 95% CI 0.33HR, 1.12; 95% CI 0.22--5.77; *p* = 0.90HR, 3.57; 95% CI 0.44--29.23; *p* = 0.24 Cisplatin, bolusHR, 1.25; 95% CI 0.25--6.23; *p* = 0.78HR, 2.74; 95% CI 0.80HR, 0.82; 95% CI 0.15--4.59; *p* = 0.82HR, 2.20; 95% CI 0.24--19.85; *p* = 0.48 CarboplatinHR, 1.41; 95% CI 0.30--6.59; *p* = 0.66HR, 1.15; 95% CI 0.31HR, 1.79; 95% CI 0.39--8.33; *p* = 0.46HR, 0.82; 95% CI 0.07--9.11; *p* = 0.87 CetuximabHR, 1.91; 95% CI 0.44--8.31; *p* = 0.39HR, 1.18; 95% CI 0.34HR, 1.09; 95% CI 0.23--5.13; *p* = 0.91HR, 1.70; 95% CI 0.20--14.11; *p* = 0.63 Cetuximab and cisplatinHR, 0.51; 95% CI 0.05--5.71; *p* = 0.59HR, 1.13; 95% CI 0.23HR, 1.00; 95% CI 0.13--7.77; *p* = 1.00HR, 1.36; 95% CI 0.09--21.88; *p* = 0.83

Factors that influence overall survival {#Sec9}
---------------------------------------

Two-year OS progressively diminished with higher pre-treatment neutrophil nadir with tertiles 1, 2 and 3 at 93.0, 86.0 and 78.5%, respectively (p = 0.03). These results are shown in Fig. [1](#Fig1){ref-type="fig"}a. On both UVA and MVA, all neutrophil time-points (pre-treatment, post-treatment and overall nadir) correlated a higher neutrophil count to worse OS (Table [3](#Tab3){ref-type="table"}). The pre-treatment NLR was additionally predictive of OS on both UVA (HR, 1.07; 95% CI 1.01--1.14; *p* = 0.02) (Table [3](#Tab3){ref-type="table"}) and MVA (HR, 1.09; 95% CI 1.01--1.17; *p* = 0.03) (Table [4](#Tab4){ref-type="table"}). A summary of UVA for all outcome measures is shown in Table [5](#Tab5){ref-type="table"}. The MVA for pre-treatment neutrophil count and OS including all patient characteristics is shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2.Fig. 1Unadjusted Kaplan--Meier curve demonstrating **a** overall survival, **b** cancer-specific survival, **c** local control and **d** distant control for pre-treatment neutrophil counts of ≤3.2 × 1000 mm^3^ (*blue*), 3.2--4.4 × 1000 mm^3^ (*green*) and \>4.4 × 1000 mm^3^ (*red*). Cox-regression UVA reflects pre-treatment neutrophil count as a continuous variable Table 3Univariate analysis of neutrophil count, lymphocyte count and NLR at each time pointNeutrophil countLymphocyte countNLRHR95% CI*p*HR95% CI*p*HR95% CI*p*Overall nadir (n = 196) Overall survival1.271.09--1.47*\<0.01*1.600.93--2.760.091.010.98--1.050.51 Cancer-specific survival1.140.99--1.310.070.860.45--1.620.631.010.98--1.040.50 Local control1.231.04--1.46*0.02*1.530.83--2.830.181.000.95--1.050.92 Distant control1.180.95--1.490.140.380.08--1.750.211.051.01--1.10*0.01*Pre treatment (n = 194) Overall survival1.211.02--1.44*0.03*1.030.68--1.550.891.071.01--1.14*0.02* Cancer-specific survival1.221.05--1.41*\<0.01*1.180.85--1.630.331.040.98--1.110.17 Local control1.160.95--1.420.151.410.97--2.050.071.050.96--1.140.31 Distant control1.371.09--1.47*\<0.01*1.450.95--2.210.091.000.89--1.131.00Post treatment (n = 136) Overall survival1.291.06--1.56*0.01*1.100.36--3.350.871.030.98--1.080.31 Cancer-specific survival1.250.99--1.570.060.470.12--1.890.291.040.99--1.100.10 Local control1.471.16--1.86*\<0.01*1.420.39--5.120.601.040.99--1.090.17 Distant control1.180.88--1.570.271.650.47--5.810.440.980.91--1.060.67 Table 4Multivariate analysis of hematologic factors significant on UVAMultivariate AnalysisHR95% CI*p*Overall neutrophil nadir (n = 196) Overall survival1.361.12--1.66\<0.01 Distant control1.321.01--1.730.05Pre treatment neutrophil count (n = 194) Overall survival1.281.02--1.610.03 Cancer-specific survival1.321.10--1.59\<0.01 Distant control1.481.13--1.95\<0.01Post treatment neutrophil count (n = 136) Overall survival1.351.04--1.740.02 Local control1.581.21--2.07\<0.01Overall NLR Distant control1.061.01--1.110.02Pre treatment NLR Overall survival1.091.01--1.170.03 Table 5Summary of prognostic factors on univariate analysisOverall survivalCancer-specific survivalLocal controlDistant controlPre-treatment neutrophil count•••Post-treatment neutrophil count••Overall neutrophil nadir••Pre-treatment lymphocyte countPost-treatment lymphocyte countOverall lymphocyte nadirPre-treatment NLR•Post-treatment NLROverall NLR•• Denotes *p* ≤ 0.05 for the respective parameter on cox-regression

Factors that influence cancer-specific and disease-free survival {#Sec10}
----------------------------------------------------------------

Similar to the OS findings, 2-year CSS progressively diminished with higher pre-treatment neutrophil nadir with tertiles 1, 2 and 3 at 86.0, 76.0 and 73.5%, respectively (p = 0.009) Fig. [1](#Fig1){ref-type="fig"}b). This was consistent on MVA with pre-treatment neutrophil count portending poor CSS (HR, 1.32; 95% CI 1.10--1.59; *p* = \<0.01) (Table [4](#Tab4){ref-type="table"}).

Factors that influence local control {#Sec11}
------------------------------------

Pre-treatment neutrophil count in tertiles 1 through 3 indicated that 2-year LC was 92.5, 84.5 and 82.5%, respectively, which was not statistically significant (Fig. [1](#Fig1){ref-type="fig"}c). On both UVA and MVA, a higher post-treatment neutrophil count correlated to worse LC (HR, 1.47; 95% CI 1.16--1.86; *p* = \<0.01 (Table [3](#Tab3){ref-type="table"}) and HR, 1.58; 95% CI 1.21--2.07; *p* = \<0.01 (Table [4](#Tab4){ref-type="table"}), respectively).

Factors that influence distant control {#Sec12}
--------------------------------------

Between tertiles 1 and 2, 2-year DC for pre-treatment neutrophil count was 96 and 93%, respectively, while tertile 3 was 79% (p = \<0.01) (Fig. [1](#Fig1){ref-type="fig"}d). On MVA, a higher pre-treatment neutrophil count was also shown to predict worse DC (Table [4](#Tab4){ref-type="table"}). On both UVA and MVA, a higher overall NLR correlated to worse DC (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, respectively).

Discussion {#Sec13}
==========

To date, the clinical significance of circulating blood counts in patients with HNSCC continues to be defined. Here we show that the circulating neutrophil count and NLR may each be independent prognostic indicators in HNSCC patients. Most impressive among these findings is that neutrophil counts were found to correlate with all outcome measures with a higher pre-treatment neutrophil count emerging as a particularly strong portent of worse OS, CSS and DC.

These findings add to the growing body of evidence that a higher pre-treatment neutrophil count portends adverse survival and treatment outcomes in cancer patients \[[@CR13], [@CR17]--[@CR19]\] and align with those who have linked baseline neutrophil count and neutrophil nadir to OS in non-small cell lung cancer and ovarian cancer \[[@CR32]\]. In addition, these findings now have a prospective correlate with the recent release of the LAP 07 trial demonstrating that neutrophilia portends poor OS in pancreatic carcinoma \[[@CR33]\]. While prior studies have noted a correlation with OS and neutrophil count in HNSCC, we present the first to directly correlate the neutrophil count to CSS, LC and DC.

In conjunction with this intriguing neutrophil data, we also support prior evidence demonstrating poor survival in HNSCC patients with high pre-treatment NLR \[[@CR24]--[@CR27], [@CR34]--[@CR36]\]. While this confirmation is encouraging, we did not see a correlation between NLR and CSS or tumor control as was seen prominently with neutrophil counts.

In contrast with the current literature, we did not find the lymphocyte count to be a prognostic indicator for survival. While several studies have shown higher circulating lymphocyte counts to improve OS \[[@CR24], [@CR28]\], there are a number of reasons why these counts could be unreliable with the most critical question being whether or not all circulating lymphocytes are functional in the setting of malignancy. Lymphocyte exhaustion and dysfunction in malignancy have been well described in HNSCC \[[@CR37], [@CR38]\], possibly stemming from impairment of natural killer cell function and dysfunction in antigen presentation. This suggests that the circulating lymphocyte count may have variable significance and thus limit the prognostic value of the ALC.

Despite the understanding that systemic chemotherapy has the potential to decrease circulating WBC, this was not deemed a significant factor in our analysis. It is additionally necessary to state that our analysis does not serve to implicate the therapeutic regimens as the cause of leukocyte changes, but rather to form an initial understanding of the prognostic importance of the leukocyte count irrespective of the cause.

Developing a firmer grasp on prognostic factors and their reliability is particularly critical as approximately 60% of HNSCC patients present with locally advanced disease \[[@CR39]\]. Despite recent improvements, the majority of patients with locally advanced disease go on to develop local and/or regional recurrences and approximately one in four develop distant metastases \[[@CR40], [@CR41]\]. According to our findings, neutrophil counts and neutrophil-associated inflammation represent promising avenues for exploration, particularly with accumulating, though still controversial, evidence suggesting that neutrophils have the capacity to facilitate tumor growth and metastasis. Specifically in HNSCC, Trellakis et al. showed that tumor infiltration with high numbers of polymorphonuclear lymphocytes (PMNs) in advanced HNSCC is a poor prognostic indicator for survival \[[@CR10]\].

While originally assumed to be a harmless indicator of a failed immune response, neutrophils may in fact have a detrimental effect by supporting the development, growth, and progression of tumors \[[@CR42], [@CR43]\]. One hypothesis asserts that immune cells are recruited to potential metastatic sites, where they secrete factors that facilitate tumor cell survival and growth, creating a permissive growth environment for tumor cells \[[@CR43]\]. Once at the pre-metastatic site, bone marrow-derived cells secrete factors that facilitate tumor cell survival and growth \[[@CR34], [@CR35]\]. Neutrophils in particular have been implicated in promoting tumor growth and angiogenesis via the secretion of pro-angiogenic factors including MMP9 and VEGF \[[@CR36]\].

The connection of neutrophils with distant metastasis has additionally been attributed to tumor "piggybacking" on neutrophils to traverse the endothelium \[[@CR44], [@CR45]\]. Further, preferential blockade of neutrophil chemotactic factors including IL-8 has been shown to promote extracellular matrix (ECM) degradation, a critical step in allowing tumor cells to access the vasculature \[[@CR44]\]. While the precise mechanism of neutrophil-assisted metastasis is still unclear, evidence suggests that the presence of cytokines including TGF-β and IFN-β may influence neutrophil signaling to serve a pro-metastatic function via immunosuppression \[[@CR45]\]. This is supported by a study showing that neutrophils isolated from spleens of tumor-bearing mice inhibited the generation of effector CD8+ T-cells \[[@CR46]\]. Finally, neutrophils in animal models have been shown during high-inflammatory states to produce extracellular DNA webs, known as neutrophil extracellular traps (NETs), that neutralize antigenic cells, while their presence in the setting of malignant cells predicts an increased risk of distant metastases \[[@CR9]\].

Conclusions {#Sec14}
===========

In summary, circulating blood counts represent easily measured, reproducible, and objective clinical marker of systemic inflammation in cancer patients. Our results demonstrate that the pre-treatment neutrophil count can serve as an independent prognostic indicator of survival and distant control in oropharyngeal and laryngeal cancer patients undergoing definitive treatment. Lymphocyte count is not an indicator of survival. The pre-treatment NLR, however, does correlate to OS. There are inherent limitations to our analysis including the retrospective approach of data collection, combination of two HNSCC sub-sites, heterogeneous response to therapy and the potential for unknown confounders impacting patient outcomes. While further studies are certainly needed to validate circulating and infiltrating markers for risk stratification and response to therapy in HNSCC, these findings augment our current understanding of the role of neutrophils and lymphocytes in tumor metastasis and survival.

Additional file {#Sec15}
===============

**Additional file 1: Table S1.** Outcomes by raw difference in neutrophil count from pre-treatment to post-treatment (n = 196). **Table S2.** Multivariate predictors of overall survival.
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